FDA, MS

FDA Tacks Boxed Warning on Teva’s Copaxone, Other MS Drugs
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since December 1996 and six patient deaths.
FDA Adds Boxed Warning to MS Drug Copaxone
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated with the use of Coxapone and the generic Glatopa that have resulted in hospitalization or death.
FDA issues warning on anaphylaxis risk with MS drugs
The FDA has added a boxed warning, its most serious designation, to Copaxone and Glatopa due to the risk of anaphylaxis, a rare but serious allergic reaction. This severe reaction can occur at any time during treatment, including months or years after starting the drug, according to a Jan. 22 news release from the agency.
FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe conditions,
FDA Warns About Anaphylaxis Risk With MS Drug
The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer acetate (Copaxone, Glatopa), the agency announced on Wednesday. The warning indicates that anaphylaxis can occur at any time, from as early as after the first dose or after doses administered years after starting treatment.
FDA: Anaphylaxis Risk Prompts Boxed Warning for MS Drug
Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
FDA adds boxed warning to Teva’s Copaxone for allergic reaction
The Food and Drug Administration is adding a boxed warning about the risk of an allergic reaction for Teva‘s (TEVA) Copaxone and Sandoz’s
SCOTUSblog6h
Supreme Court likely to let vape company’s FDA challenge proceed
At oral arguments earlier this week the Supreme Court was skeptical of the Food and Drug Administration’s effort to block a North Carolina-based company from challenging the denial of its application ...
A popular skincare product is part of nationwide FDA recall. Do you have this moisturizer?
The U.S. Food and Drug Administration has issued a recall on a popular skin moisturizer that's available nationwide. Do you have this product?
Hosted on MSN5d
Mississippi Insight for Jan. 19, 2025: Dortch and Latino
Jarvis Dortch with the ACLU of Mississippi discusses legislative redistricting, while Magnolia Tribune's Russ Latino examines ...
SCOTUSblog3d
Menthol vapes and forum shopping, FDA tobacco control comes before justices
The Supreme Court will hear oral arguments on Tuesday in a clash over whether a North Carolina-based company can challenge the Food and Drug Administration’s denial of its application to market ...